Dynamic analysis of gh receptor conformational changes by split luciferase complementation

Molecular Endocrinology

Volumn 28, Issue 11, 2014, Pages 1807-1819

  Liu, Ying ^a   Berry, Philip A ^a   Zhang, Yue ^a   Jiang, Jing ^a   Lobie, Peter E ^c   Paulmurugan, Ramasamy ^d   Langenheim, John F ^e   Chen, Wen Y ^e   Zinn, Kurt R ^b   Frank, Stuart J ^a,b,f  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e CLEMSON UNIVERSITY   (United States)

^f BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN RECEPTOR; ESTROGEN RECEPTOR; FIREFLY LUCIFERASE; GROWTH HORMONE; GROWTH HORMONE RECEPTOR; HOMODIMER; JANUS KINASE 2; LUCIFERASE; CARRIER PROTEIN; JAK2 PROTEIN, HUMAN; PROTEIN BINDING; SOMATOTROPIN-BINDING PROTEIN;

AMINO TERMINAL SEQUENCE; ARTICLE; BIOASSAY; CARBOXY TERMINAL SEQUENCE; CHIMERA; CONCENTRATION (PARAMETERS); CONFORMATIONAL TRANSITION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SPLIT LUCIFERASE COMPLEMENTATION; CELL LINE; GENETICS; METABOLISM; PHOSPHORYLATION; PROTEIN TERTIARY STRUCTURE; SIGNAL TRANSDUCTION;

CARRIER PROTEINS; CELL LINE; GROWTH HORMONE; HUMANS; JANUS KINASE 2; LUCIFERASES; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; SIGNAL TRANSDUCTION;

EID: 84908349618     PISSN: 08888809     EISSN: 19449917     Source Type: Journal    
DOI: 10.1210/me.2014-1153     Document Type: Article

References (66)

1. Isaksson OG, Eden S, Jansson JO. Mode of action of pituitary growth hormone on target cells. Annu Rev Physiol. 1985;47:483-499.
2. Kaplan S. Hormonal regulation of growth and metabolic effects of growth hormone. In: Kostyo J, Goodman HM, eds. Handbook of Physiology. New York: Oxford University Press; 1999:129-143.
3. Moller N, Jorgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev. 2009;30:152-177.
4. Waters MJ, Hoang HN, Fairlie DP, Pelekanos RA, Brown RJ. New insights into growth hormone action. J Mol Endocrinol. 2006;36: 1-7.
5. Wang Z, Luque RM, Kineman RD, et al. Disruption of growth hormone signaling retards prostate carcinogenesis in the probasin/ TAg rat. Endocrinology. 2008;149:1366-1376.
6. Zhang X, Mehta RG, Lantvit DD, et al. Inhibition of estrogen-independent mammary carcinogenesis by disruption of growth hormone signaling. Carcinogenesis. 2007;28:143-150.
7. Wang Z, Prins GS, Coschigano KT, et al. Disruption of growth hormone signaling retards early stages of prostate carcinogenesis in the C3(1)/T antigen mouse. Endocrinology. 2005;146:5188-5196.
8. Coschigano KT, Holland AN, Riders ME, List EO, Flyvbjerg A, Kopchick JJ. Deletion, but not antagonism, of the mouse growth hormone receptor results in severely decreased body weights, insulin, and insulin-like growth factor I levels and increased life span. Endocrinology. 2003;144:3799-3810.
9. Bonkowski MS, Rocha JS, Masternak MM, Al Regaiey KA, Bartke A. Targeted disruption of growth hormone receptor interferes with the beneficial actions of calorie restriction. Proc Natl Acad Sci USA. 2006;103:7901-7905.
10. Ikeno Y, Hubbard GB, Lee S, et al. Reduced incidence and delayed occurrence of fatal neoplastic diseases in growth hormone receptor/ binding protein knockout mice. J Gerontol A Biol Sci Med Sci. 2009;64:522-529.
11. Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, et al Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci Transl Med. 2011;3:70-13.
12. Swanson SM, Unterman TG. The growth hormone-deficient Spontaneous Dwarf rat is resistant to chemically induced mammary carcinogenesis. Carcinogenesis. 2002;23:977-982.
13. Shen Q, Lantvit DD, Lin Q, et al. Advanced rat mammary cancers are growth hormone dependent. Endocrinology. 2007;148:4536-4544.
14. Ramsey MM, Ingram RL, Cashion AB, et al. Growth hormone-deficient dwarf animals are resistant to dimethylbenzanthracine (DMBA)-induced mammary carcinogenesis. Endocrinology. 2002; 143:4139-4142.
15. Steuerman R, Shevah O, Laron Z. Congenital IGF1 deficiency tends to confer protection against post-natal development of malignancies. Eur J Endocrinol. 2011;164:485-489.
16. Bazan JF. Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci USA. 1990;87:6934-6938.
17. Argetsinger LS, Campbell GS, Yang X, et al. Identification of JAK2 as a growth hormone receptor-associated tyrosine kinase. Cell. 1993;74:237-244.
18. Frank SJ, Gilliland G, Kraft AS, Arnold CS. Interaction of the growth hormone receptor cytoplasmic domain with the JAK2 ty-rosine kinase. Endocrinology. 1994;135:2228-2239.
19. Frank SJ, Yi W, Zhao Y, et al. Regions of the JAK2 tyrosine kinase required for coupling to the growth hormone receptor. J Biol Chem. 1995;270:14776-14785.
20. Vanderkuur JA, Wang X, Zhang L, et al. Domains of the growth hormone receptor required for association and activation of JAK2 tyrosine kinase. J Biol Chem. 1994;269:21709-21717.
21. Gent J, van Kerkhof P, Roza M, Bu G, Strous GJ. Ligand-indepen-dent growth hormone receptor dimerization occurs in the endoplas-mic reticulum and is required for ubiquitin system-dependent en-docytosis. Proc Natl Acad Sci USA. 2002;99:9858-9863.
22. Brown RJ, Adams JJ, Pelekanos RA, et al. Model for growth hormone receptor activation based on subunit rotation within a receptor dimer. Nat Struct Mol Biol. 2005;12:814-821.
23. Yang N, Wang X, Jiang J, Frank SJ. Role of the growth hormone (GH) receptor transmembrane domain in receptor predimerization and GH-induced activation. Mol Endocrinol. 2007;21:1642-1655.
24. de Vos AM, Ultsch M, Kossiakoff AA. Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science. 1992;255:306-312.
25. Cunningham BC, Ultsch M, De Vos AM, Mulkerrin MG, Clauser KR, Wells JA. Dimerization of the extracellular domain of the human growth hormone receptor by a single hormone molecule. Science. 1991;254:821-825.
26. Fuh G, Cunningham BC, Fukunaga R, Nagata S, Goeddel DV, Wells JA. Rational design of potent antagonists to the human growth hormone receptor. Science. 1992;256:1677-1680.
27. Rowlinson SW, Yoshizato H, Barclay JL, et al. An agonist-induced conformational change in the growth hormone receptor determines the choice of signalling pathway. Nat Cell Biol. 2008;10:740-747.
28. Frank SJ. Receptor dimerization in GH and erythropoietin action—it takes two to tango, but how? Endocrinology. 2002;143: 2-10.
29. Deng L, Jiang J, Frank SJ. Growth hormone-induced JAK2 signaling and GH receptor down-regulation: role of GH receptor intra-cellular domain tyrosine residues. Endocrinology. 2012;153:2311-2322.
30. He K, Wang X, Jiang J, et al. Janus kinase 2 determinants for growth hormone receptor association, surface assembly, and signaling. Mol Endocrinol. 2003;17:2211-2227.
31. He K, Loesch K, Cowan JW, et al. Janus kinase 2 enhances the stability of the mature growth hormone receptor. Endocrinology. 2005;146:4755-4765.
32. Deng L, He K, Wang X, et al. Determinants of growth hormone receptor down-regulation. Mol Endocrinol. 2007;21:1537-1551.
33. Loesch K, Deng L, Wang X, He K, Jiang J, Frank SJ. Endoplasmic reticulum-associated degradation of growth hormone receptor in Janus kinase 2-deficient cells. Endocrinology. 2007;148:5955-5965.
34. Loesch K, Deng L, Cowan JW, et al. JAK2 influences growth hormone receptor metalloproteolysis. Endocrinology. 2006;147: 2839-2849.
35. Pang X, Zhou HX. A common model for cytokine receptor activation: combined scissor-like rotation and self-rotation of receptor dimer induced by class I cytokine. PLoS Comput Biol. 2012;8: e1002427.
36. Brooks AJ, Dai W, O’Mara ML, et al. Mechanism of activation of protein kinase JAK2 by the growth hormone receptor. Science. 2014;344:1249783.
37. Yang N, Langenheim JF, Wang X, Jiang J, Chen WY, Frank SJ. Activation of growth hormone receptors by growth hormone and growth hormone antagonist dimers: insights into receptor triggering. MolEndocrinol. 2008;22:978-988.
38. Zhang Y, Guan R, Jiang J, et al. Growth hormone (GH)-induced dimerization inhibits phorbol ester-stimulated GH receptor proteolysis. J Biol Chem. 2001;276:24565-24573.
39. Jiang J, Liang L, Kim SO, Zhang Y, Mandler R, Frank SJ. Growth hormone-dependent tyrosine phosphorylation of a GH receptor-associated high molecular weight protein immunologically related to JAK2. Biochem Biophys Res Commun. 1998;253:774-779.
40. Zhang Y, Jiang J, Kopchick JJ, Frank SJ. Disulfide linkage of growth hormone (GH) receptors (GHR) reflects GH-induced GHR dimerization. Association of JAK2 with the GHR is enhanced by receptor dimerization. J Biol Chem. 1999;274:33072-33084.
41. Alele J, Jiang J, Goldsmith JF, Yang X, et al. Blockade of growth hormone receptor shedding by a metalloprotease inhibitor. Endocrinology. 1998;139:1927-1935.
42. Kim SO, Jiang J, Yi W, Feng GS, Frank SJ. Involvement of the Src homology 2-containing tyrosine phosphatase SHP-2 in growth hormone signaling. J Biol Chem. 1998;273:2344-2354.
43. Jiang J, Wang X, He K, et al. A conformationally-sensitive GHR [growth hormone (GH) receptor] antibody: impact on GH signaling and GHR proteolysis. Mol Endocrinol. 2004;18:2981-2996.
44. Jiang J, Wan Y, Wang X, et al. Inhibitory GH receptor extracellular domain monoclonal antibodies: three-dimensional epitope mapping. Endocrinology. 2011;152:4777-4788.
45. Kohlhuber F, Rogers NC, Watling D, et al. A JAK1/JAK2 chimera can sustain a and y interferon responses. Mol Cell Biol. 1997;17: 695-706.
46. Paulmurugan R, Gambhir SS. Firefly luciferase enzyme fragment complementation for imaging in cells and living animals. Anal Chem. 2005;77:1295-1302.
47. Paulmurugan R, Gambhir SS. An intramolecular folding sensor for imaging estrogen receptor-ligand interactions. Proc Natl Acad Sci USA. 2006;103:15883-15888.
48. Luker KE, Smith MC, Luker GD, Gammon ST, Piwnica-Worms H, Piwnica-Worms D. Kinetics of regulated protein-protein interactions revealed with firefly luciferase complementation imaging in cells and living animals. Proc Natl Acad Sci USA. 2004;101: 12288-12293.
49. Villalobos V, Naik S, Piwnica-Worms D. Detection of protein-protein interactions in live cells and animals with split firefly luciferase protein fragment complementation. Methods Mol Biol. 2008;439: 339-352.
50. Yang KS, Ilagan MX, Piwnica-Worms D, Pike LJ. Luciferase fragment complementation imaging of conformational changes in the EGF receptor. J Biol Chem. 2009;284(12):7474-7482.
51. Macdonald-Obermann JL, Adak S, Landgraf R, Piwnica-Worms D, Pike LJ. Dynamic analysis of the EGF receptor-ErbB2-ErbB3 network by luciferase fragment complementation imaging. J Biol Chem. 2013;288(42):30773-30784.
52. Macdonald-Obermann JL, Piwnica-Worms D, Pike LJ. Mechanics of EGF receptor/ErbB2 kinase activation revealed by luciferase fragment complementation imaging. Proc Natl Acad Sci USA. 2012;109:137-142.
53. Paulmurugan R, Massoud TF, Huang J, Gambhir SS. Molecular imaging of drug-modulated protein-protein interactions in living subjects. Cancer Res. 2004;64:2113-2119.
54. Paulmurugan R, Umezawa Y, Gambhir SS. Noninvasive imaging of protein-protein interactions in living subjects by using reporter protein complementation and reconstitution strategies. Proc Natl Acad Sci USA. 2002;99:15608-15613.
55. Paulmurugan R, Tamrazi A, Massoud TF, Katzenellenbogen JA, Gambhir SS. In vitro and in vivo molecular imaging of estrogen receptor a and β homo- and heterodimerization: exploration of new modes of receptor regulation. Mol Endocrinol. 2011;25:2029-2040.
56. Defour JP, Itaya M, Gryshkova V, et al. Tryptophan at the trans-membrane-cytosolic junction modulates thrombopoietin receptor dimerization and activation. Proc Natl Acad Sci USA. 2013;110: 2540-2545.
57. Luker KE, Gupta M, Steele JM, Foerster BR, Luker GD. Imaging ligand-dependent activation of CXCR7. Neoplasia. 2009;11: 1022-1035.
58. Biener-Ramanujan E, Ramanujan VK, Herman B, Gertler A. Spatio-temporal kinetics of growth hormone receptor signaling in single cells using FRET microscopy. Growth Horm IGF Res. 2006;16: 247-257.
59. Goffin V, Bernichtein S, Carriere O, Bennett WF, Kopchick JJ, Kelly PA. The human growth hormone antagonist B2036 does not interact with the prolactin receptor. Endocrinology. 1999;140: 3853-3856.
60. Kopchick JJ, Parkinson C, Stevens EC, Trainer PJ. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr Rev. 2002;23:623-646.
61. Sedek M, van der Velden LM, Strous GJ. Multimeric growth hormone receptor complexes serve as signaling platforms. J Biol Chem. 2014;289:65-73.
62. Huang Y, Kim S-O, Yang N, Jiang J, Frank SJ. Physical and functional interaction of GH and IGF-1 signaling elements. Mol Endo-crinol. 2004;18:1471-1485.
63. Frank SJ, Gilliland G, Van Epps C. Treatment of IM-9 cells with human growth hormone (GH) promotes rapid disulfide linkage of the GH receptor. Endocrinology. 1994;135:148-156.
64. Hedvat M, Huszar D, Herrmann A, et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell. 2009;16:487-497.
65. McFarland BC, Ma JY, Langford CP, et al. Therapeutic potential of AZD1480 for the treatment of human glioblastoma. Mol Cancer Ther. 2011;10:2384-2393.
66. Frank SJ, Fuchs SY. Modulation of growth hormone receptor abundance and function: roles for the ubiquitin-proteasome system. Biochim Biophys Acta. 2008;1782:785-794.